Active Ingredient History
Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors. It is FDA approved for the treatment of schizophrenia, bipolar mania, irritability associated with autistic disorder. Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. Vice versa, Fluoxetine, paroxetine, and other CYP 2D6 enzyme inhibitors increase plasma concentrations of risperidone. Common adverse reactions include increased mortality in elderly patients with dementia-related psychosis, cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis, neuroleptic malignant syndrome, tardive dyskinesia , metabolic Changes (hyperglycemia and diabetes mellitus, dyslipidemia, weight gain), hyperprolactinemia, orthostatic hypotension, leukopenia, neutropenia, agranulocytosis, potential for cognitive and motor impairment, seizures, dysphagia, priapism, disruption of body temperature regulation. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma (Phase 2)
Adjustment Disorders (Phase 3)
Affective Disorders, Psychotic (Phase 4)
Aggression (Phase 4)
Alcoholism (Phase 4)
Alzheimer Disease (Phase 4)
Analgesics, Opioid (Early Phase 1)
Anorexia Nervosa (Phase 4)
Antipsychotic Agents (Phase 4)
Anxiety (Phase 4)
Anxiety Disorders (Phase 4)
Asperger Syndrome (Phase 4)
Autism Spectrum Disorder (Phase 4)
Behavior, Addictive (Early Phase 1)
Borderline Personality Disorder (Phase 4)
Breast Neoplasms (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Central Nervous System Diseases (Phase 1)
Child Behavior Disorders (Phase 3)
Child Development Disorders, Pervasive (Phase 4)
Chorea (Phase 2)
Cocaine-Related Disorders (Phase 2)
Conduct Disorder (Phase 4)
Delirium (Phase 4)
Dementia (Phase 4)
Dementia, Vascular (Phase 3)
Depression (Phase 4)
Depressive Disorder (Phase 3)
Depressive Disorder, Major (Phase 3)
Depressive Disorder, Treatment-Resistant (Phase 4)
Dermatology (Phase 4)
Developmental Disabilities (Phase 3)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Diagnosis, Dual (Psychiatry) (Phase 4)
DiGeorge Syndrome (Phase 4)
Drug Administration Schedule (Phase 4)
Drug Evaluation (Phase 2)
Drugs, Investigational (Phase 2)
Drug Therapy (Phase 4)
Dyskinesia, Drug-Induced (Phase 1)
Emergency Treatment (Phase 4)
Fasting (Phase 1)
Fragile X Syndrome (Phase 4)
Growth and Development (Phase 3)
Healthy Volunteers (Phase 4)
Hot Flashes (Phase 2)
Huntington Disease (Phase 2)
Hyperglycemia (Phase 4)
Hyperprolactinemia (Phase 4)
Immunoassay (Phase 1)
Insulin Resistance (Phase 4)
Intellectual Disability (Phase 3)
Learning Disabilities (Phase 3)
Mania (Phase 4)
Marijuana Abuse (Phase 4)
Mental Disorders (Phase 3)
Mental Health (Phase 4)
Metabolic Syndrome (Phase 4)
Methamphetamine (Phase 4)
Mood Disorders (Phase 4)
Movement Disorders (Phase 4)
Obsessive-Compulsive Disorder (Phase 2)
Opioid-Related Disorders (Early Phase 1)
Panic Disorder (Phase 4)
Pharmacogenetics (Phase 1)
Physiological Effects of Drugs (Phase 4)
Premenstrual Syndrome (Phase 2)
Psychological Distress (Phase 2)
Psychophysiologic Disorders (Phase 3)
Psychotropic Drugs (Phase 4)
Rett Syndrome (Phase 3)
Risk Factors (Phase 4)
Schizophrenia, Treatment-Resistant (Phase 2)
Schizotypal Personality Disorder (Phase 1/Phase 2)
Sexual Dysfunction, Physiological (Phase 4)
Smoking Cessation (Phase 3)
Stress Disorders, Post-Traumatic (Phase 4)
Substance-Related Disorders (Phase 4)
Therapeutic Uses (Phase 4)
Tourette Syndrome (Phase 2)
Tranquilizing Agents (Phase 4)
Traumatology (Phase 2)
Weight Gain (Phase 4)
Williams Syndrome (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
